JEJanet F. Eary

Janet F. Eary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Janet F. Eary has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 131I Therapy Using rhTSH Stimulation and Dosimetry in Metastatic Malignant Struma Ovarii

    by Jinchun Yan, David H. Lewis, Michelle F. Benoit, Janet F. Eary, David A. Mankoff

    A 38-year-old woman with metastatic malignant struma ovarii, including massive liver metastases and retroperitoneal lymphadenopathy, underwent ovarian resection and retroperitoneal lymph nodes excision, partial hepatectomy, and radiofrequency ablation for liver metastases. She underwent thyroidectomy and received three I treatments using recombinant human thyrotropin stimulation and radioiodine dosimetry. posttherapy I imaging, anatomic images, and thyroglobulin levels showed significant diminution in the tumor burdens and remarkable decline in thyroglobulin levels. This case provided valuable information on recombinant human thyrotropin-assisted I ablation in conjunction with dosimetry in an unusual presentation of iodine-avid malignant struma ovarii with bulky metastases.


  • Impact of 18F-FDG PET/CT Imaging in Therapeutic Decisions for Malignant Solitary Fibrous Tumor of the Pelvis

    by Jinchun Yan, Robin L. Jones, David H. Lewis, Janet F. Eary

    The decision to give neoadjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma is often based on tumor grade evaluated from biopsies, but biopsies can have the inherent issue of sampling bias. Incorporation of SUVmax and heterogeneity assessed by F-FDG PET/CT could be other crucial components in the effort to tailor treatment to an individual patient, providing valuable parameters to guide the selection of the most appropriate management schedule for an individual. We present 1 representative case describing how FDG PET/CT can assist in clinical management decisions for treatment of malignant solitary fibrous tumor of the pelvis.


  • Sarcoma

    by Janet F. Eary, Ernest U. Conrad

  • Open Access

    Imaging in Sarcoma

    by Janet F. Eary, Ernest U. Conrad

    Imaging has contributed to diagnosis and treatment decision making for patients with sarcomas, a highly heterogeneous tumor group. Derived from mesenchymal tissues, sarcomas occur in all parts of the body and in all patient age groups, with a highly variable histologic appearance and behavior. They are commonly separated into soft-tissue–derived and bone-derived groups; however, many exceptions to these classifications are seen clinically. Tumor size, cellular type and differentiation, and presence of necrosis are tumor features that can be used clinically to predict the risk of aggressive behavior. At present for soft-tissue sarcomas, the 5-y survival is approximately 60%, with substantially better survival for patients with bone tumors, particularly pediatric patients. Imaging with nuclear medicine techniques plays an important role in diagnosis, treatment planning, and follow-up. Conventional 99mTc-methylene diphosphonate bone scans, 201Tl tumor imaging, and PET techniques have contributed to the care of sarcoma patients. Newer PET techniques with biologically specific imaging agents have also been evaluated to characterize sarcomas and contribute to risk stratification for poor outcome.


  • Open Access

    Multiagent PET for Risk Characterization in Sarcoma

    by Janet F. Eary, Jeanne M. Link, Mark Muzi, Ernest U. Conrad, David A. Mankoff, Jedediah K. White, Kenneth A. Krohn

    A major goal of molecular imaging in cancer is to evaluate patient tumors for risk of treatment resistance and poor outcome using biologically specific PET agents. This approach was investigated using a multiagent imaging protocol for which patients were imaged in a single session to minimize changes in tumor parameters caused by multiple-day and -setting observation differences. Methods: We present data from a pilot study in 10 soft-tissue sarcoma patients imaged with 11C-thymidine for cellular proliferation, 18F-fluoromisonidazole (FMISO) for tissue hypoxia, and 11C-verapamil for P-glycoprotein activity, in comparison with 15O-water for blood flow and 11C-CO2 for metabolite analysis and 18F-FDG clinical scans. Several patients underwent repeated imaging after adriamycin-based chemotherapy. Results: Quantitative imaging results showed that tumor uptake parameters vary between patients and with respect to each other in individual patients, suggesting that each patient's tumor biologic profile is unique. Specific tumor characteristics such as variable cellular proliferation, hypoxic volume, and upregulated P-glycoprotein activity were identified. Conclusion: This study shows that multiagent PET is feasible and yields unique and potentially complementary biologic information on individual tumors.


    • 1 January 2011
      • Vol. 1  (1) , 47-53

    18F-FDG PET in sarcoma treatment response imaging

    by Janet F. Eary, Douglas S. Hawkins, Eve T. Rodler, Ernest U. Conrad

    Sarcomas are a biologically complex group of diseases that exhibit variable responses to single or combination therapy. F-18-FDG PET imaging contributes to sarcoma treatment response assessment as an objective semi-quantitative biomarker of response. In this review, background and experience in F-18-FDG PET as a biomarker that successfully identifies tumor response is assessed.


  • Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics

    by Stephanie E.W. Punt, Janet F. Eary, Janet O'SUllivan, Ernest U. Conrad

    Objective Leiomyosarcoma, a malignant neoplasm of smooth muscle, accounts for 7% of the sarcomas. Patients with leiomyosarcoma tumors have an average survival of 5 years. These tumors, which are derived from mesenchymal tissues, are difficult to diagnose, and treatment options remain controversial. The relatively rare incidence of this soft tissue sarcoma subtype has limited the number of patients available for studies and research. This study examines whether the imaging characteristics of positron emission tomography (PET) with radiolabeled fluorodeoxyglucose (FDG) provide a reliable, noninvasive means to predict tumor behavior in patients with leiomyosarcomas. Methods [18F]-FDG-PET was performed on the tumors of participating patients before the neoadjuvant chemotherapy or resection, and a maximum tumor standard uptake value (SUVmax) was calculated. Results The SUVmax was correlated with tumor grade (P=0.001) and tumor size as greatest dimension (P=0.004). Analysis of these data indicated the potential effectiveness of FDG-PET imaging in predicting tumor grade. Conclusion In leiomyosarcoma, the SUVmax from FDG-PET is a likely predictor of tumor behavior. The results of this study suggest that a large (by greatest dimension) intermediate grade tumor is expected to have the same predicted outcome as a high-grade tumor and should be treated in the same manner, as they share the same prognosis by definition of tumor grade. Improvements made in the clinical treatment of leiomyosarcomas by use of FDG-PET imaging data may lead to an increase in patient survival.


  • Open Access

    Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome

    by Janet F. Eary, Finbarr O'SUllivan, Janet O'SUllivan, Ernest U. Conrad

    18F-FDG PET images of tumors often display highly heterogeneous spatial distribution of 18F-FDG–positive pixels. We proposed that this heterogeneity in 18F-FDG spatial distribution can be used to predict tumor biologic aggressiveness. This study presents data to support the hypothesis that a new heterogeneity-analysis algorithm applied to 18F-FDG PET images of tumors in patients is predictive of patient outcome. Methods: 18F-FDG PET images from 238 patients with sarcoma were analyzed using a new algorithm for heterogeneity analysis in tumor 18F-FDG spatial distribution. Patient characteristics, tumor histology, and patient outcome were compared with image analysis results using univariate and multivariate analysis. Cox proportional hazards models were used to further analyze the significance of the data associations. Results: Statistical analyses show that heterogeneity analysis is a strong independent predictor of patient outcome. Conclusion: The new 18F-FDG PET tumor image heterogeneity analysis method is validated for the ability to predict patient outcome in a clinical population of patients with sarcoma. This method can be extended to other PET image datasets in which heterogeneity in tissue uptake of a radiotracer may predict patient outcome.